Do You Need a Tau PET Scan for a Dementia Diagnosis?

Learn when tau imaging changes care, what standard testing covers, and which questions to ask your doctor.

No, most people evaluated for dementia do not need a tau PET scan. Doctors diagnose most cases with history, exams, cognitive testing, labs, and structural brain imaging. A tau PET scan is a brain PET image that maps clumped tau protein, called tangles. The scan estimates where tangles sit and how dense they are in an adult with thinking problems who is being evaluated for Alzheimer's.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What a tau PET scan measures

Tau tangles build up inside brain cells and spread as Alzheimer's advances. A tau PET scan makes that spread visible, which helps show stage and likely course rather than give a yes-or-no diagnosis. The first tracer for this use was Tauvid, cleared by the Food and Drug Administration on May 28, 2020 to estimate tangle density and distribution, according to Tauvid prescribing information.

A second tracer, Tauklarify, was later cleared for brain PET to identify tangle pathology in adults evaluated for Alzheimer's. A positive scan alone does not prove Alzheimer's. FDA labeling warns that Tauvid does not measure amyloid and is not for evaluation of chronic traumatic encephalopathy.

Why standard testing usually answers the question

Most dementia evaluations start with medical history, cognitive tests, physical and neurologic exams, blood and other lab tests, and MRI or CT, according to the National Institute on Aging in current NIA guidance. Those steps identify common causes, rule out reversible problems, and guide next care.

For Alzheimer's specifically, the Alzheimer's Association 2024 revised criteria accept one abnormal Core 1 marker for diagnosis. That can be amyloid PET, an approved spinal-fluid test, or accurate blood p-tau217. Tau PET is generally a Core 2 marker, meaning it helps stage disease and estimate prognosis by showing how far tau has spread.

When doctors consider tau PET

Tau PET fits a narrow role. The 2025 Alzheimer's Association and SNMMI Appropriate Use Criteria find it appropriate in only five clinical situations, and only when the result will change management, according to the groups in Association guidance on appropriate use.

In practice, that means staging or prognosis questions where the answer would alter treatment, counseling, trial referral, or planning. It does not replace amyloid confirmation. Patients seeking amyloid-targeting drugs still need positive amyloid by amyloid PET or spinal-fluid testing, so tau PET alone does not establish eligibility.

What to ask before you agree

Ask how the scan would change your care. A useful order helps when the diagnosis is uncertain, the stage is unclear, or a treatment or trial decision turns on tau spread.

Bring a medication list, prior MRI or CT images, and a family member who knows your daily changes. Ask for the result in writing with the next care step attached.

  • Will this result change my diagnosis, drug choice, trial referral, or care plan
  • Which amyloid test do I still need, if any
  • Where is the scan done, how do I prepare, and who explains the result
  • What follow-up visit is planned to act on the finding

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.